Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 42

1.
2.

Drug-Induced Liver Injury in HIV Patients.

Neff GW, Jayaweera D, Sherman KE.

Gastroenterol Hepatol (N Y). 2006 Jun;2(6):430-437.

3.

Multicenter study of skin rashes and hepatotoxicity in antiretroviral-naïve HIV-positive patients receiving non-nucleoside reverse-transcriptase inhibitor plus nucleoside reverse-transcriptase inhibitors in Taiwan.

Wu PY, Cheng CY, Liu CE, Lee YC, Yang CJ, Tsai MS, Cheng SH, Lin SP, Lin DY, Wang NC, Lee YC, Sun HY, Tang HJ, Hung CC.

PLoS One. 2017 Feb 21;12(2):e0171596. doi: 10.1371/journal.pone.0171596. eCollection 2017.

4.

Assessment of the effect of antiretroviral therapy on renal and liver functions among HIV-infected patients: a retrospective study.

Wondifraw Baynes H, Tegene B, Gebremichael M, Birhane G, Kedir W, Biadgo B.

HIV AIDS (Auckl). 2016 Dec 22;9:1-7. doi: 10.2147/HIV.S120979. eCollection 2017.

5.

CIHR Canadian HIV Trials Network Coinfection and Concurrent Diseases Core Research Group: 2016 Updated Canadian HIV/Hepatitis C Adult Guidelines for Management and Treatment.

Hull M, Shafran S, Wong A, Tseng A, Giguère P, Barrett L, Haider S, Conway B, Klein M, Cooper C.

Can J Infect Dis Med Microbiol. 2016;2016:4385643. doi: 10.1155/2016/4385643. Epub 2016 Jul 4.

6.

Liver Damage in Patients with HCV/HIV Coinfection Is Linked to HIV-Related Oxidative Stress.

Huang X, Liang H, Fan X, Zhu L, Shen T.

Oxid Med Cell Longev. 2016;2016:8142431. doi: 10.1155/2016/8142431. Epub 2016 Jan 10.

7.

Progression of Liver Fibrosis and Modern Combination Antiretroviral Therapy Regimens in HIV-Hepatitis C-Coinfected Persons.

Brunet L, Moodie EEM, Young J, Cox J, Hull M, Cooper C, Walmsley S, Martel-Laferrière V, Rachlis A, Klein MB; Canadian Co-infection Cohort Study, Cohen J, Conway B, Cooper C, Côté P, Cox J, Gill J, Haider S, Sadr A, Johnston L, Hull M, Montaner J, Moodie E, Pick N, Rachlis A, Rouleau D, Sandre R, Tyndall JM, Vachon ML, Sanche S, Skinner S, Wong D.

Clin Infect Dis. 2016 Jan 15;62(2):242-249. doi: 10.1093/cid/civ838. Epub 2015 Sep 23.

8.

Transient Elastography for the Detection of Liver Damage in Patients with HIV.

Sagir A, Glaubach B, Sahin K, Graf D, Erhardt A, Oette M, Häussinger D.

Infect Dis Ther. 2015 Sep;4(3):355-64. doi: 10.1007/s40121-015-0073-y. Epub 2015 Jul 5.

9.

Evaluating Liver Fibrosis by Transient Elastometry in Patients With HIV-HCV Coinfection and Monoinfection.

Brescini L, Orsetti E, Gesuita R, Piraccini F, Marchionni E, Staffolani S, Castelli P, Drenaggi D, Barchiesi F.

Hepat Mon. 2014 Aug 5;14(8):e15426. doi: 10.5812/hepatmon.15426. eCollection 2014 Aug.

10.

Evaluating the utility of early laboratory monitoring of antiretroviral-induced haematological and hepatic toxicity in HIV-infected persons in Cameroon.

Bekolo CE, Sonkoue C, Djidjou H, Bekoule PS, Kollo B.

BMC Infect Dis. 2014 Sep 25;14:519. doi: 10.1186/1471-2334-14-519.

11.

Noncommunicable diseases in HIV infection in low- and middle-income countries: gastrointestinal, hepatic, and nutritional aspects.

Kelly P, Saloojee H, Chen JY, Chung RT.

J Acquir Immune Defic Syndr. 2014 Sep 1;67 Suppl 1:S79-86. doi: 10.1097/QAI.0000000000000260. Review.

12.
13.

CIHR Canadian HIV Trials Network Coinfection and Concurrent Diseases Core: Canadian guidelines for management and treatment of HIV/hepatitis C coinfection in adults.

Hull M, Klein M, Shafran S, Tseng A, Giguère P, Côté P, Poliquin M, Cooper C.

Can J Infect Dis Med Microbiol. 2013 Winter;24(4):217-38. Erratum in: Can J Infect Dis Med Microbiol. 2014;24(1):63.

14.

Hepatic safety and tolerability of raltegravir among HIV patients coinfected with hepatitis B and/or C.

Hurt CB, Napravnik S, Moore RD, Eron JJ Jr.

Antivir Ther. 2014;19(4):415-22. doi: 10.3851/IMP2738. Epub 2014 Jan 23.

15.

Serious Non-AIDS events: Immunopathogenesis and interventional strategies.

Hsu DC, Sereti I, Ananworanich J.

AIDS Res Ther. 2013 Dec 13;10(1):29. doi: 10.1186/1742-6405-10-29.

16.

Changes to antiretroviral drug regimens during integrated TB-HIV treatment: results of the SAPiT trial.

Naidoo A, Naidoo K, Yende-Zuma N, Gengiah TN, Padayatchi N, Gray AL, Bamber S, Nair G, Karim SS.

Antivir Ther. 2014;19(2):161-9. doi: 10.3851/IMP2701. Epub 2013 Oct 31.

17.

EFV/FTC/TDF-associated hepatotoxicity: a case report and review.

Echenique IA, Rich JD.

AIDS Patient Care STDS. 2013 Sep;27(9):493-7. doi: 10.1089/apc.2013.0008. Epub 2013 Aug 12. Review.

18.

Liver Function Profile Anomalies in HIV Seropositive Tuberculosis.

Dey SK, Ghosh I, Bhattacharjee D, A P, Jha S, Dasgupta A, Dey SK.

J Clin Diagn Res. 2013 Jun;7(6):1068-72. doi: 10.7860/JCDR/2013/5156.3047. Epub 2013 Jun 1.

19.

Predictors of the change in bilirubin levels over twelve weeks of treatment with atazanavir.

Cotter AG, Brown A, Sheehan G, Lambert J, Sabin CA, Mallon PW.

AIDS Res Ther. 2013 May 16;10(1):13. doi: 10.1186/1742-6405-10-13. No abstract available.

20.

Focus on the liver: alcohol use, highly active antiretroviral therapy, and liver disease in HIV-infected patients.

Barve S, Kapoor R, Moghe A, Ramirez JA, Eaton JW, Gobejishvili L, Joshi-Barve S, McClain CJ.

Alcohol Res Health. 2010;33(3):229-36. Review.

Supplemental Content

Support Center